Chordia Therapeutics Inc. (TYO:190A)

Japan · Delayed Price · Currency is JPY

68.00

-1.00 (-1.45%)

Sep 16, 2026, 3:30 PM JST

Chordia Therapeutics Financials Overview

Financials in millions JPY. Fiscal year is September - August.

Millions JPY. Fiscal year is Sep - Aug.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	May '26 May 31, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023
Revenue	-	-	-	2,500
Revenue Growth	-	-	-	-
Gross Profit	-	-	-	2,500
Operating Income	-1,440	-1,790	-1,801	212.06
Net Income	-1,434	-1,786	-1,827	223.34
Earnings Per Share	-20.02	-26.03	-31.11	3.96
EPS Growth	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	May '26 May 31, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023
Net Cash (Debt)	2,507	2,549	4,330	4,799
Net Cash Growth	-11.17%	-41.13%	-9.78%	-
Net Cash Per Share	34.99	37.15	73.72	85.02
Cash & Investments	2,507	2,549	4,330	4,799

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	May '26 May 31, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023
Operating Cash Flow	-	-1,837	-1,937	543.73
Capital Expenditures	-	-5.33	-0.54	-0.35
Free Cash Flow	-	-1,842	-1,938	543.38
Free Cash Flow Growth	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	May '26 May 31, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023
Gross Margin	-	-	-	100.00%
Operating Margin	-	-	-	8.48%
Pretax Margin	-	-	-	9.03%
Profit Margin	-	-	-	8.93%
FCF Margin	-	-	-	21.73%

Valuation

Selected indicators aren't available for this stock.